Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Cambrex Corporation, frequently known as Cambrex, stands as a premier global contract development and manufacturing organisation (CDMO). Headquartered in East Rutherford, New Jersey, USA, Cambrex operates a vast network of state-of-the-art facilities spanning North America, Europe, and Asia. This extensive geographical footprint underpins its unwavering commitment to driving pharmaceutical innovation worldwide.
As a leader in medicinal and botanical manufacturing, Cambrex provides integrated drug substance (API) development, manufacturing, and drug product services. With over 40 years of expertise, the company delivers comprehensive, end-to-end solutions for small molecule therapeutics, from early-stage development through to commercial production. Its unique offering includes bespoke analytical services and advanced manufacturing capabilities, ensuring robust pharmaceutical supply chains for global clients.
-9 vs industry average
Cambrex Corporation’s score of 8 is lower than 23% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Medicinal and Botanical Manufacturing is among the most carbon-intensive industries
The Medicinal and Botanical Manufacturing industry has reduced its overall emissions by 28% since 2018
No reported emissions data is available for Cambrex Corporation yet.
Cambrex Corporation, a US-headquartered company in Medicinal and Botanical Manufacturing, has committed to ambitious climate targets through the Science Based Targets initiative (SBTi).
Cambrex Corporation has set near-term Science Based Targets (SBTs) to significantly reduce its greenhouse gas emissions. The company commits to an absolute reduction of Scope 1 and 2 GHG emissions by 51.6% by 2030, using 2018 as a base year. Additionally, Cambrex Corporation pledges to reduce absolute Scope 3 GHG emissions from purchased goods and services, fuel- and energy-related activities, and upstream transportation and distribution by 42% by 2030, against a 2020 base year. These targets are consistent with the reductions required to limit global warming to 1.5°C.
2030
51.6% reduction in Scope 2
Cambrex Corporation commits to reduce absolute scope 1 and 2 GHG emissions 51.6% by 2030 from a 2018 base year.
2030
51.6% reduction in Scope 1
Cambrex Corporation commits to reduce absolute scope 1 and 2 GHG emissions 51.6% by 2030 from a 2018 base year.
2030
42% reduction in scope 3 total
Cambrex Corporation also commits to reduce absolute scope 3 GHG emissions from purchased goods and services, fuel- and energy-related activi…
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Cambrex Corporation’s sustainability data and climate commitments
Data year: 2022
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more